IGC Pharma, Inc. (IGC) is a publicly traded Industrials sector company. As of October 13, 2026, IGC trades at $0.27 with a market cap of $28.94M and a P/E ratio of -3.11. IGC moved -4.38% today. Year to date, IGC is -1.92%; over the trailing twelve months it is -30.84%. Its 52-week range spans $0.24 to $0.50. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces IGC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IGC Pharma targets commercial rollout of PRISM layer for Alzheimer’s risk assessment and cognitive monitoring: IGC Pharma launched PRISM and plans to commercialize it through B2B, B2B2C and online channels for clinical and consumer use. The company said its CALMA Phase 2 trial of IGC-AD1 remains on track for topline results in Q4 2026.
| Metric | Value |
|---|---|
| Price | $0.27 |
| Market Cap | $28.94M |
| P/E Ratio | -3.11 |
| EPS | $-0.09 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.50 |
| 52-Week Low | $0.24 |
| Volume | 162.59K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.27M |
| Net Income | $-7.12M |
| Gross Margin | 48.70% |
1 analysts cover IGC: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.